• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高危葡萄胎患者在葡萄胎妊娠清宫时使用或不使用一剂放线菌素D作为预防性化疗后的生殖结局。

Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy.

作者信息

Uberti Elza Maria Hartmann, Fajardo Maria do Carmo, Ferreira Silvia Villa Verde Ribeiro, Pereira Maurício Vannoni, Seger Raquel Cristina, Moreira Maria Amélia Rolla, Torres Magali Duarte, de Nápoli Gilberto, Schmid Helena

机构信息

TDC of CHSCPA, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.

出版信息

Gynecol Oncol. 2009 Dec;115(3):476-81. doi: 10.1016/j.ygyno.2009.09.012. Epub 2009 Oct 8.

DOI:10.1016/j.ygyno.2009.09.012
PMID:19818481
Abstract

OBJECTIVE

To evaluate whether prophylactic chemotherapy (P-chem) with one bolus dose of actinomycin D (Act-D) during the uterine evacuation of patients with high-risk hydatidiform mole (Hr-HM) affects reproductive outcomes in subsequent pregnancies.

METHODS

From 1987 to 2006, 1090 patients with gestational trophoblastic disease (GTD) were evaluated at a Trophoblastic Disease Center in southern Brazil; 265 with Hr-HM were selected and retrospectively analyzed. From 1996 to 2006, 163 received one bolus dose of Act-D at the time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-chem (Hr-HM-control group). In March 2009, the number of pregnancies, progression of first pregnancy, and association of low age and low parity with subsequent pregnancy were evaluated.

RESULTS

The percentage of patients that became pregnant was similar in both groups (Hr-HM-control: 59.5%; Hr-HM-chem group: 45.7%; p=0.069) and independent of HM progression. Percentages of no pregnancies because of age (> or =40 years) or hysterectomy were also similar. Type of subsequent pregnancy was not statistically different between groups, and the rate of live births associated with pregnancies for which US showed a live fetus was high. Frequency of repeat GTD was unexpectedly high in both groups (4.2% and 6.3%; p=1.00).

CONCLUSIONS

P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups.

摘要

目的

评估在高危葡萄胎(Hr-HM)患者清宫时给予单剂量放线菌素D(Act-D)进行预防性化疗(P-chem)是否会影响其后续妊娠的生殖结局。

方法

1987年至2006年期间,巴西南部的一个滋养细胞疾病中心对1090例妊娠滋养细胞疾病(GTD)患者进行了评估;选取其中265例Hr-HM患者进行回顾性分析。1996年至2006年期间,163例患者在清宫时接受了单剂量Act-D(Hr-HM-化疗组);102例具有相同危险因素的患者未接受P-chem(Hr-HM-对照组)。2009年3月,评估了妊娠次数、首次妊娠进展情况以及低年龄和低产次与后续妊娠的相关性。

结果

两组患者的妊娠率相似(Hr-HM-对照组:59.5%;Hr-HM-化疗组:45.7%;p = 0.069),且与葡萄胎进展无关。因年龄(≥40岁)或子宫切除而未妊娠的比例也相似。两组后续妊娠类型无统计学差异,超声显示有活胎的妊娠活产率较高。两组中复发性GTD的发生率均意外地高(4.2%和6.3%;p = 1.00)。

结论

P-chem对Hr-HM患者的生殖结局无影响。两组中再次妊娠的患者正常妊娠活产率均较高。低年龄和低产次亚组后续妊娠的机会更高。

相似文献

1
Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy.高危葡萄胎患者在葡萄胎妊娠清宫时使用或不使用一剂放线菌素D作为预防性化疗后的生殖结局。
Gynecol Oncol. 2009 Dec;115(3):476-81. doi: 10.1016/j.ygyno.2009.09.012. Epub 2009 Oct 8.
2
Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment.在高危葡萄胎中使用单次大剂量放线菌素D预防磨牙后妊娠滋养细胞肿瘤:一种简单、有效、安全且低成本的方法,对总体随访依从性或后续治疗无不良影响。
Gynecol Oncol. 2009 Aug;114(2):299-305. doi: 10.1016/j.ygyno.2009.04.006. Epub 2009 May 8.
3
Single-dose actinomycin D: Efficacy in the prophylaxis of postmolar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole.单剂量放线菌素D:对高危葡萄胎青少年患者预防性治疗妊娠滋养细胞肿瘤的疗效。
Gynecol Oncol. 2006 Aug;102(2):325-32. doi: 10.1016/j.ygyno.2005.12.036. Epub 2006 Feb 14.
4
An analysis of the influences of maternal age, gestational age, contraceptive method, and the mode of primary treatment of patients with hydatidiform moles on the incidence of subsequent chemotherapy.对葡萄胎患者的母亲年龄、孕周、避孕方法及初次治疗方式对后续化疗发生率的影响进行分析。
Br J Obstet Gynaecol. 1979 Oct;86(10):782-92. doi: 10.1111/j.1471-0528.1979.tb10694.x.
5
[Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high-risk hydatidiform mole].高危葡萄胎患者预防性化疗效果及临床特征分析
Zhonghua Fu Chan Ke Za Zhi. 2011 Jan;46(1):24-7.
6
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.预防性化疗用于葡萄胎以预防妊娠滋养细胞肿瘤。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD007289. doi: 10.1002/14651858.CD007289.pub2.
7
Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study.葡萄胎随访环境对葡萄胎后妊娠滋养细胞肿瘤结局的影响:一项队列研究
J Reprod Med. 2012 Jul-Aug;57(7-8):305-9.
8
[The reproductive function following a hydatidiform mole].[葡萄胎后的生殖功能]
J Gynecol Obstet Biol Reprod (Paris). 1984;13(1):67-76.
9
Prophylactic actinomycin D for high-risk complete hydatidiform mole.高危完全性葡萄胎预防性应用放线菌素D。
J Reprod Med. 2001 Feb;46(2):110-6.
10
Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.完全性或部分性葡萄胎妊娠后复发性葡萄胎的风险及后续妊娠结局
BJOG. 2003 Jan;110(1):22-6.

引用本文的文献

1
The role of single-dose prophylactic methotrexate in the prevention of post-molar gestational trophoblastic neoplasia in patients with high-risk molar pregnancy.单剂量甲氨蝶呤预防性治疗在高危葡萄胎患者中的作用。
BMC Cancer. 2024 Nov 13;24(1):1400. doi: 10.1186/s12885-024-13162-0.
2
Centralized surveillance of hydatidiform mole: 7-year experience from a regional hospital in China.集中监测葡萄胎:中国一家地区医院 7 年的经验。
Int J Gynecol Cancer. 2022 Feb;32(2):147-152. doi: 10.1136/ijgc-2021-002797. Epub 2021 Nov 19.
3
Type II non-ribosomal peptide synthetase proteins: structure, mechanism, and protein-protein interactions.
II 型非核糖体肽合成酶蛋白:结构、机制和蛋白-蛋白相互作用。
Nat Prod Rep. 2020 Mar 25;37(3):355-379. doi: 10.1039/c9np00047j.
4
Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study.比较至少 40 岁的完全性葡萄胎妇女不同治疗策略:一项回顾性队列研究。
BMC Cancer. 2017 Nov 9;17(1):733. doi: 10.1186/s12885-017-3749-8.
5
Manipulating Protein-Protein Interactions in Nonribosomal Peptide Synthetase Type II Peptidyl Carrier Proteins.调控II型非核糖体肽合成酶肽基载体蛋白中的蛋白质-蛋白质相互作用
Biochemistry. 2017 Oct 10;56(40):5269-5273. doi: 10.1021/acs.biochem.7b00884. Epub 2017 Oct 2.
6
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.预防性化疗用于葡萄胎以预防妊娠滋养细胞肿瘤。
Cochrane Database Syst Rev. 2017 Sep 11;9(9):CD007289. doi: 10.1002/14651858.CD007289.pub3.
7
In vitro antimicrobial, antioxidant and cytotoxic properties of Streptomyces lavendulae strain SCA5.薰衣草链霉菌菌株SCA5的体外抗菌、抗氧化和细胞毒性特性
BMC Microbiol. 2014 Nov 30;14:291. doi: 10.1186/s12866-014-0291-6.
8
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.预防性化疗用于葡萄胎以预防妊娠滋养细胞肿瘤。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD007289. doi: 10.1002/14651858.CD007289.pub2.